AstraZeneca's rare disease innovative drug approved in China

Sina Finance reported on March 30th that AstraZeneca announced that the National Medical Products Administration of China has officially approved the use of hydrogen sulfide simvastatin capsules for the treatment of type 1 neurofibromatosis children and adult patients with symptomatic, inoperable plexiform neurofibromatosis aged 3 and older. This is currently the first and only approved treatment for this patient population aged 3 and older in the country.